In addition, we validated the prognostic value of LAMP2 in a variety of cancers including LUAD, GBMLGG, breast cancer, colorectal cancer, blood cancer (follicular lymphoma), and soft tissue cancer (liposarcoma) using PrognoScan based on the GEO dataset (Supplementary Table 1). Here, LAMP2 is linked to breast cancer.